1247 results about "Tumor patient" patented technology

The invention provides a curcumin oral emulsion and injection, wherein the emulsion comprises curcumin, oil, emulsifying agent and water, the injection also contains isotonic agent. The invention also discloses the process for preparing the emulsion and its use in preparing medicaments for treating or preventing tumor, resisting tumor transfer, enhancing curative effects of chemotherapy drugs, reducing side effects of chemotherapy and improving immunity functions for tumor patients.

The invention provides a formulation for a special prandial food, which contains short peptides and is provided for tumor sufferers to eat. The food uses food-originated short peptides as raw materials which are added with extracts of medical-edible Chinese herbal medicines such as champignons, dried orange peels, Chinese wolfberry, yams, tuckahoes, rhizoma polygonati, and the like, and compound complex formulation. With the food formulation, powdered or granular foods can be prepared and are dissolved with warm water to eat. The food prepared according to the formulation is easy to dissolve, can be absorbed and utilized quickly, provides a high quality nitrogen source for organisms, supplements various vitamins and minerals necessary for a human body, can correct the negative nitrogen balance of the tumor sufferers, improve the nutritional status of the tumor sufferers, and can play a role in improving organism immunity and suppressing and resisting cancers through the combined action of various factors such as bioactive components, the functional oligosaccharides, and the like in the food-originated short peptides and the extracts of the medical-edible Chinese herbal medicines, thus the food is suitable for the tumor sufferers, particularly for cancer patients who receive radiation therapy and chemotherapy to eat.

The invention discloses a PD-1 gene recombinant virus. The collection number of the recombinant virus Lenti-PD-1-Puro is CCTCC No:V201601. According to the PD-1 gene recombinant virus, PD-1gRNA sequences are cloned into a retrovirus plasmid Lenti-CRISPR / Cas9-Puro, and a PD-1 recombinant virus plasmid Lenti-CRISPR / Cas9-PD-1-Puro is obtained; then the PD-1 recombinant virus plasmid Lenti-CRISPR / Cas9-PD-1-Puro, a plasmid pSPAX and pMD2.G are jointly transfected by 293T cells, and packaging of the recombinant virus Lenti-PD-1-Puro is completed. After T cells of peripheral blood of tumor patients are infected by the PD-1 recombinant virus, PD-1 on the T cells is successfully knocked out, the inhibitory state of the T cells of the tumor patients is relieved, the capacity of attacking tumor cells of the T cells embellished by the PD-1 recombinant virus is recovered accordingly, and the effect of immune cell treating is achieved.

The invention discloses cotton fibers with antibacterial and insect-resisting effects. The cotton fibers are characterized by being prepared from the following raw materials in parts by weight: 21-24 parts of cotton fibers, 10-12 parts of apocynum venetum fibers, 6-8 parts of silk fibers, 7-9 parts of cashmere fibers, 9-11 parts of pineapple fibers, 4-7 parts of polypropylene fibers, 6-8 parts of taxus chinensis superfine micro-powder, 3-5 parts of ailanthus altissima leaf extracted powder, 1-3 parts of zeolite powder, 1.1-2.3 parts of chitosan, 0.5-0.7 part of magnesium nitride, 0.8-1.4 parts of N,N-dicyanoethylaniline, 5-7 parts of sulfonated castor oil, 15-18 parts of fatty alcohol alkoxy ether, 1-2 parts of mashed garlic, 1.3-2.5 parts of cnidium monnieri cuss, 2.1-3.6 parts of coptis chinensis, 90-95 parts of 1-ethyl-3-methylimidazolium diethylphosphate, 95-100 parts of 1-butyl-3-methylimidazolium acetate, 3-6 parts of an addition agent and a proper amount of water. According to the cotton fibers, the taxus chinensis superfine micro-powder is added into raw materials by adopting an ultrasonic technology and a prepared cotton textile has a very good health effect and a useful pain-relieving effect on tumor patients and female symptoms; furthermore, the other active ingredients are added so that the good clothes properties of sweat absorption, breathability, softness, allergy prevention, easiness of washing, low probability of fuzzing and balling up and the like of natural cotton fibers are maintained, and the cotton fibers have good antibacterial and insect-resisting functions, a good electromagnetic radiation shielding function and the like.

The invention discloses an anti-human CLDN18.2 antibody as well as an antigen binding fragment and a medical application thereof. Specifically, the present invention relates to a murine antibody comprising a CDR region of the anti-human CLDN18.2 antibody, a chimeric antibody and a humanized antibody, a fully humanized antibody, an antibody-dependent cytotoxicity (ADCC) comprising the antibody andthe antigen binding fragment thereof, complement dependent cytotoxicity (CDC), the killing effect on CLDN18.2 positive cells, the effect of inhibiting the growth of CLDN18.2 positive tumors, the in-vivo drug effect, a medicine containing the anti-human CLDN18.2 antibody and the antigen binding fragment thereof, a composition of the medicine thereof, and an application of the medicine in tumor treatment, in particular to treatment of CLDN18.2 positive tumor patients..

The invention relates to nutrition formula food applicable to a tumor patient, and aims at providing nutrition formula food which is applicable to the tumor patient and is prepared according to pathological characteristics of metabolic disorder of the tumor patient. The nutrition formula food applicable to the tumor patient, per 100kcal thermal content, comprises 3.8-5.8g protein or hydrolysate of the protein, 5.6-8.4g carbohydrate, 4.8-7.2g fat, 0.9-1.4g dietary fiber, 3.31-108.62mg vitamin complex, 0-40mg taurine and 0.33-2.333g complex mineral. The food has the main characteristics that the food contains unbalance amino acid, high protein, slow-release carbohydrate, and high fat, and has high energy density; the treatment effect of the patient is better than that of a patient supported by ordinary nutrition after the food provides clinical nutrition support for the patient undergoing lung cancer chemotherapy; and the complication rate of the patient is also obviously lower than that of the patient supported by the ordinary nutrition.

A whole-nutrient enteric emulsion for tumor patient is prepared through dissolving or dispersing the raw solid materials in purified water while stirring to obtain water-phase mixture, mixing it with oil-phase mixture to obtain emulsion, adding residual purified water, stirring while removing foam, high-pressure homogenizing, cooling, storing, pouring glass bottles, aerating nitrogen, sealing and steam sterilizing.

Apparatus and method for the precision aiming of a radiation beam for treating an internal cancer tumor in a patient. The method of treatment includes introducing at least one reference marker into the patient in a defined and locatable position in relation to the cancer tumor. A defined point in the cross section of the beam is located by a sight that is compared to the position of the reference marker and adjusted to ensure that the treatment beam is directed precisely at the cancer tumor before the remaining doses of radiation are given to the patient. The device according to the invention includes equipment for emitting a treatment beam, a sight arranged in the path of the beam to define a point in the cross section of the beam, and a device to read the beam arranged to receive the beam that has passed through the patient and visualize the position of the at least one said reference marker and the position of the sight.

The invention provides a method to reduce the rate of tumor metastasis and tumor recurrence after surgery and chemotherapy and radiotherapy by removing circulating tumor cells (CTC) in the blood after surgery and chemotherapy and radiotherapy by means of specificity, thereby improving the survival rate of cancer patients. The invention provides a method and a system for removing tumor cells. Patients ' blood is guided out to pass through a container, an antibody or a ligand capable of combining with the specificity of the tumor cells is fixed on a solid-phase carrier in the container, whne the patients ' blood passes through the container, the tumor cells can be absorbed by the specificity to be unable to flow back to patients ' blood, and then the tumor cells are removed from the blood to reduce the recidivation of tumor patients and to prolong their survival rate. The removed tumor cells can be washed out from the solid-phase carrier for counting. The invention further provides a method to remove pathogen from blood. Blood is withdrawn from a patient and its plasma and cellular components are separated by means of a plasma separator under the effect of a blood pump, the plasma portion inactivates the pathogen in the blood via a pathogen inactivating device, flows back to extracorporeal circulation passage to merge with the cellular components and then is returned to the patient. The method adopts a physical means, so that side effects can be reduced. The device is simple in structure and can be connected with other blood purification devices.

The problem to be solved by the present invention is to provide an anticancer agent for treating tumors resistant to other antitumor agents that inhibit FGFR, and a method for treating such tumors. The present invention provides an antitumor agent for administration to a tumor patient resistant to an FGFR inhibitor, the antitumor agent comprising a 3,5-disubstituted benzene alkynyl compound represented by Formula (I) below or a salt thereof. The present invention also provides a therapeutic method using the anticancer agent.

The invention discloses an expansion method of various lymphocyte subpopulations and application of the expansion method to preparation of an adoptive immunotherapy medicine for cancers. The expansion method comprises the following steps: S1, adding IFN gamma and zoledronic acid into a culture medium of PBMC collected in the blood of a tumor patient, and re-adding an OKT3 antibody and recombinant human interleukin-2 after culture to stimulate PBMC so as to finish preliminary expansion; S2, after finish of preliminary expansion, mixing immune lymphocytes with feeder layer cells, and after adding zoledronic acid, an OKT3 antibody and recombinant human interleukin-2, continually performing expansion. By adoption of the expansion method, after twice expansion, the sum of the immune cells can be 10,000 to 80,000 times by expansion, the expanded immune cells include alpha beta T cells, gamma delta T cells, NKT cells and NK cells, and tumor cells can be directly killed, or a cellular immunotherapy drug is prepared to kill the tumor cells.

The invention discloses a transcriptome-based tumor antigen identification method. The method comprises four steps of: obtaining an RNA sample of a patient tumor tissue, and carrying out library construction and amplification on the RNA sample to obtain an RNA sample sequencing result of the tumor tissue; aligning short read segments of the RNA sample sequencing result to a human reference genometo obtain an RNA alignment result; calculating gene expression quantity according to the RNA alignment result, and carrying out mutation detection and prediction of fusion gene events according to theRNA alignment result; and predicting transcriptome HLA typing according to the alignment result, wherein calculation of the gene expression quantity, mutation detection and prediction of the fusion gene events are carried out according to a specified order or simultaneously carried out; and using the gene expression quantity of a transcriptome sample, depth of transcriptome mutation sites in a whole-exon sequencing sample and binding force of neonatal short peptides and the patient HLA typing as an analysis result to submit the same to a downstream analyst. The invention provides the method capable of identifying a tumor-specific antigen of an individual sample from tumor patient transcriptome NGS data.

The invention discloses a spleen polypeptide extract extracted from the spleen tissue of mammals other than humans. The mammalian tissue is subjected to fat removal, homogenization, acid adjustment, freezing and thawing, pH adjustment, precipitation, heating, and centrifugation. Filtration, ultrafiltration and other steps to obtain the spleen polypeptide extract; the drug is an immunomodulatory drug that can improve and improve the immune function of the body, and can be used for primary and secondary cellular immune deficiency diseases (such as eczema, thrombocytopenia, multiple Infection syndrome, etc.), respiratory tract and lung infection, habitual cold, chronic hepatitis B, mumps, recurrent aphtha and other diseases, can be used in the treatment of leukopenia, leukemia, aplastic anemia caused by radiotherapy and chemotherapy , Lymphoma and other malignant tumors, to improve the malignant transformation of tumor patients, to improve postoperative or critically ill patients when they are weak.

The invention relates to an intelligent tumor medication instruction system. The intelligent tumor medication instruction system is characterized by comprising a patient information module, a gene mutation detection module, a medication instruction database and a detection result reporting module, wherein the patient information module is used for recording the basic information of a patient; the gene mutation detection module is used for detecting the gene mutation information of the patient, such as a gene name, a mutation site, mutation conditions, mutation frequency and germline mutation and / or somatic cell mutation; the medication instruction database is used for performing medication instruction and query according to the clinical information of the patient, automatically matching and sequencing the clinical information and the medication instruction and query results, and sending an optimum medication instruction scheme suitable for the tumor patient to the detection result reporting module; a doctor can instruct the medication on the tumor patient according to the medication scheme displayed by the detection result reporting module. The intelligent tumor medication instruction system is widely applied to the diagnosis and medication instruction process of the tumor patient.

The invention provides a high-energy enteral nutrition multi polymerizer. The total energy of every 100g of the multi polymerizer is 450-500kJ. The energy ratio is as follows: 16-20% of protein, 35-50% of fat and 40-50% of carbohydrate. The multi polymerizer has the advantages of high fat, high energy, low carbohydrate and rich nutrition, meets the nutritional treatment guideline of modern medicine relevant to malignant tumor, has the obvious anti-tumor effect, and can improve the nutrition condition of tumor patients.

The invention relates to application of a 20(S)-ginsenoside Rh2, namely 20(S)-protopanoxadiol-3-O-beta-D-glucopyranoside compound in the field of pharmacy. The compound can confront the swimming fatigue action of tumor-bearing animals and enhance the oxygen deficit resistance and immunologic function of the tumor-bearing animals. The safety experiment shows that the compound has high safety, does not influence the central nervous system, cardiovascular system and respiratory system of animals, and has no mutagenesis function. The clinical research shows that the compound can effectively reduce the brief fatigue index BFI score of a tumor patient, improve the functional evaluation FACTIT-F score of chronic disease treatment, improve the KPS score, and simultaneously relieve Chinese medicine symptoms so as to improve the fatigue degree of the tumor patient. The compound has high safety and good anti-fatigue function under test dose, and can be used for the treatment of fatigue, in particular cancer related fatigue.

The invention discloses a tumor isocenter multi-angle non-planar percutaneous puncture method belonging to a novel method that a doctor carries out tumor percutaneous puncture on a tumor patient under the guidance of CT in the technical field of medical treatment, and solving the problems of high dependence on experiences and techniques of an operator, easy generation of larger puncture errors, long occupation time of puncture, large difficulty in puncturing smaller tumors or deeper tumors in early stage, and low success rate in the tumor percutaneous puncture technology. The technical scheme is as follows: the tumor isocenter multi-angle non-planar percutaneous puncture method comprises the steps of sharing an isocenter by a center point of a semi-circular piercer and a center point of a tumor through coordinate system transfer, and driving a puncture needle for realizing multi-angle non-planar puncture through sliding of an arrow rest and rotating of the piercer. The tumor isocenter multi-angle non-planar percutaneous puncture method has the advantages that the problems of high dependence on experiences and techniques of the operator, easy generation of larger puncture errors, long occupation time of puncture, large difficulty in puncturing smaller tumors or deeper tumors in early stage, and low success rate in the tumor percutaneous puncture technology are solved, vital organs, puncture taboo organs and taboo focuses can be effectively avoided, the tumor percutaneous puncture error can be shortened to 2mm under the guidance of the CT, and the highest tumor percutaneous puncture precision at home and abroad is achieved.

The invention discloses a chimeric antigen receptor T cell capable of conducting allograft and a preparation method. The T cell is transformed through the gene fixed-point knockout technology, especially the CRISPR / Cas9 technology, gene knockout is conducted for the constant areas of chains alpha and beta of TCR of the T cell so that TCR of the T cell can be inactivated, and the T cell can conduct allograft without causing immunological rejection. The T cell with the inactivated TCR is combined with the CAR technology, and therefore the aim of treating specific tumors in a targeted mode through the T cell with the allograft source can be achieved. The chimeric antigen receptor T cell and the method overcome the defects that at present, T cells of patients are small in number, low in activity and long in culture time. High-quality and high-activity T cells in blood of healthy people can be used for transforming in advance, CART cells for various tumors are prepared, tumor patients do not need to wait once needing CART treatment, the precious time of treatment wait is shortened to the maximum extent.

The invention relates to a clinical nutrient formula special for tumor and a preparation method of the clinical nutrient formula. The clinical nutrient formula is prepared from the following raw materials: proteins, fat, a carbohydrate, dietary fibers, macroelements, trace elements, fat-soluble vitamins, water-soluble vitamins, a medicinal and edible component, a natural plant compound and new resource food, wherein the medicinal and edible component is selected from at least one of hawthorns, sea-buckthorn, poria cocos, sealwort, chrysanthemum, dandelion, lilies and fermented soybean; all the components are prepared into powder; the fat is prepared into powdered oil by adopting a micro capsule embedding technology. Due to screening and proportioning of the components, the nutrient formula disclosed by the invention can supply comprehensive nutrition support to a tumor patient and substantially increase the biological value of the proteins; moreover, due to the adding of the components capable of enhancing the immunity and resisting the tumor, the physique of the tumor patient can be enhanced, and malnutrition which possibly occurs or exists can be prevented or corrected; the nutrition supporting effect is enhanced, so that the patient can bear a complete chemotherapy process.

The invention relates to a glycopeptide mixture product and application thereof in preparing a medicament for improving the nutritional status and immunologic function of tumor patients receiving radiotherapy and chemotherapy and health food or food. A glycopeptide mixture is prepared by mixing marine oligopeptide and bioactive polysaccharide according to certain proportion. The marine oligopeptide is a group of oligopeptide mixtures with low molecular weights which are produced by taking fish skin, fish meat or fish bone of marine fishes as main raw materials through enzymatic hydrolysis, can be dissolved by trichloroacetic acid, and have relative molecular mass less than 1,000, and has the characteristics of easy absorption, quick absorption, low viscosity, good water solubility, and the like. The bioactive polysaccharide comprises lentinan, ganoderan, grifola polysaccharide, panaxan, lycium bararum polysaccharide and algal polysaccharide. Animal experiments and clinical observation prove that the glycopeptide mixture prepared by mixing the marine oligopeptide and the bioactive polysaccharide has the effect of improving the immunologic function of tumor-bearing mice and the nutritional status of the tumor patients receiving radiotherapy and chemotherapy.

The invention discloses a reagent for detection of an ROR1 protein in circulating blood and an application thereof, and particularly discloses the reagent for the detection of the ROR1 protein of circulating tumor cells in peripheral blood. The reagent includes an ROR1 antibody, a buffer solution, a marker, a nuclear dye and a lymphocyte identification antibody. A characteristic that ROR1 is only expressed in cancer cells and is not expressed in normal adult tissue cells is utilized, and the reagent is applied to detect the expressed ROR1 protein of the circulating tumor cells or tumor stem cells in the circulating blood, wherein the circulating tumor cells or the tumor stem cells fall off from a primary tumor nidus into the blood; limitations of a traditional method are overcome, and the accuracy and the reliability of the detection of the circulating tumor cells are greatly improved. The reagent can be used for helping detect the tumor cells in the circulating blood of a tumor patient, and is a potential breakthrough point for tumor disease diagnosis, evaluation of therapeutic effects and cancer metastasis monitoring.

The invention belongs to the field of medicine and gene engineering, and provides a composition for inhibiting the proliferation of tumor cells. The composition contains epigallocatechin gallate (EGCG) and daunorubicin (DNR), and the mass ratio of the epigallocatechin gallate to the daunorubicin is 600: 1-1: 2. The combination of the EGCG and the DNR, on one hand, ensures that the effect of inhibiting the proliferation of the tumor cells is more obvious than the superposition of single use effects, on the other hand, the combination of the EGCG and the DNR obviously reduces the using amount of the DNR, greatly reduces the cardiac toxicity of the DNR, and strengthens the anti-tumor effect of the DNR at the same time. The EGCG is a natural tea extract, has rich resource and low price, and almost has no toxic side effect after more than one thousand years of drinking, so the combination of the EGCG and the DNR relatively reduces the using amount of the DNR and drug cost. The invention provides a high-efficiency cheap anti-tumor pharmaceutical composition, which improves the inhibition rate of tumor and reduces the treatment cost of tumor patients at the same time.

The invention discloses new medicinal uses of chlorogenic acid, especially uses of chlorogenic acid in preparation of drugs treating multidrug resistance of cancer, and provides uses of chlorogenic acid and antitumor drugs in preparation of drugs treating cancer. By inhibiting activity and expression of drug pump protein on surfaces of tumor cells, tumor patients generating multidrug resistance can receive durable and effective treatment. A combination of the chlorogenic acid and a drug-resistant drug is provided, thus alleviating or eliminating drug resistance to multiple drugs for patients, allowing patients with drug resistance to receive durable and effective treatment, and overcoming the limitation problem at present that tumor patients cannot receive durable and effective treatment due to generation of drug resistance. The uses have important meaning in clinical use of antitumor treatment.

The invention belongs to the medicine field, and specifically relates to an intra-intestinal nutrient emulsion for tumor patients. The emulsion is characterized by comprises the following effective components: protein, fat, carbohydrate, total dietary fiber, green tea theine, taurine, L-carnitine, composite vitamins and mineral substances, and water. The protein is provided in an amino acid powder form, the formula of the amino acid powder is adjusted on the basis of 20 kinds of protein amino acids, wherein methionine is replaced by homocysteine, glutamine and glutamic acid are not added, the tryptophan content is low, and the content of branched chain amino acid reaches 35% or more; fat is provided in a saturated aliphatic acid or unsaturated fatty acid form, wherein in the unsaturated aliphatic acid the value of omega-6 / omega-3 is equal to 2-6 / 1; and the carbohydrate is provided in a form of glycerin, glucose, fructo-oligosaccharide or lentinan. Besides one prominent characteristic of the emulsion is that the emulsion is a high-fat and low-sugar type, and the ratio of sugar to fat is 1:1. The emulsion formula is adjusted according to the nutrient and metabolism requirements of tumor patients so as to develop an individualized intra-intestinal nutrient preparation for tumor patients, the preparation can provide balanced nutrients for tumor patients, effectively cures the malnutrition symptom, improves the life quality of patients, and can also be used to assist the tumor treatment.

The invention provides a high-specificity high-sensitivity coordinated compound anti-human-TK1 antibody prepared from an antigenic determinant composed of human cervical cancer cell TK1 monomer N-terminal 23 peptide, C-terminal 20 peptide and C-terminal 28 peptide, and application thereof in tumor diagnosis. The antigenic determinant contains the following amino acid sequences: N-terminal 23 peptide (3-25): CINLPTVLPGSPSKTRGQIQVIL, C-terminal 20 peptide (206-225) CPVPGKPGEAVAARKLFAPQ, and C-terminal 28 peptide (198-225) AGPDNKENCPVPGKPGEAVAARKLFAPQ. The invention also relates to a method for preparing the antibody prepared from the antigen. The antibody kit provided by the invention has the characteristics of high sensitivity, high specificity, low cost and the like. The treatment effect on the tumor patient is evaluated by an enhanced chemiluminescent point blotting detection method, immunohistochemical detection and the detection kit.

The invention relates to a functionality nutritional meal replacing food suitable for tumor patients. The food mainly comprises the components according to the mass percent: 10-30 parts of wheat seed, 4-10 parts of tuckahoe, 4-10 parts of Chinese yam, 4-10 parts of barbary wolfberry, 4-10 parts of fried white lablab bean, 1.5-4.5 parts of black sesame, 1.5-4.5 parts of mushroom extractive containing 20% of lentinan, 1.5-4.5 parts of dandelion extractive with 10:1 of herbal withdrawal ratio, 1.5-4.5 parts of bare peach kernel, 1-3 parts of spirulina platensis or spirulina maxima, 1-3 parts of pure fructus amomi and 6-66 parts of brown rice. The invention well solves the problems of the tumor patients (chemotherapy) such as poor appetite, poor eating, anorexia, nausea vomiting, being unableto eat anymore, has more comprehensive nutrition and is suitable for being used as the meal replacing food of the tumor patients, has auxiliary functions on body immunity enhancement, anti-tumor and relapse prevention and can obviously lighten the concurrent chemoradiotherapy gastrointestinal tract reaction. The invention also relates to a preparation method for the meal replacing food.

The invention discloses a method for obtaining a tumor specific T cell receptor. The method comprises the following steps: firstly, obtaining a T cell receptor gene sequence in an antigen peptide specific T cell which comes from an immunoreactive positive and / or tumor symptom relieved tumor patient after antigen peptide treatment; then, preparing an antigen specific T cell receptor according to the antigen specific T cell receptor gene sequence; introducing the antigen peptide specific T cell receptor gene into the T cell, and expressing the antigen peptide specific T cell receptor gene to obtain the specific TCR-T cell. The specific TCR-T cell can be used for successfully killing gene mutation corresponding to antigen peptide and HLA typed tumor cell, and has high killing efficiency and agood application prospect.

The invention relates to a tumor inhibitory peptide capable of being specifically bound with PD-1 and an application thereof. The inhibitory peptide can be bound with an extracellular region of a PD-1 protein receptor and can effectively close a PD-1 protein at protein level and cellular level and prevent the PD-1 protein from being bound with a ligand PD-L1. The polypeptide has good biological activity. The polypeptide can be used in tumor immunotherapy alone or combined with an anti-PD-1 monoclonal antibody or other anti-tumor drugs as well as diagnosis and screening of a PD-1 positive tumor patient, namely the polypeptide can be applied to preparation of drugs used for treating tumor and autoimmune diseases.

The invention discloses a novel heptacyclic compound (2'S,5'S)-tetrahydropyrazine[1',2':1,6]bis{(1S)-1-methyl-2,3,4,9-tetrahydro-1H-pyridine[3,4-b]diindole}-1',4'-diketone (ZMC for short), discloses apreparation method thereof, discloses an anti- thrombosis function thereof, discloses an anti-inflammation effect thereof, disclosed an anti-tumor effect thereof, and further discloses a free radicalscavenging effect and a P-selectin expression inhibiting effect thereof. Thus, the invention discloses application of the ZMC to preparation of a P-selectin-targeted medicament capable of inhibitingthrombosis, inflammation and tumors. Since the thrombosis and the inflammation are most common complications of tumor patients, the ZMC disclosed by the invention can be used for not only treating thetumors, but also preventing the complications of the thrombosis and the inflammation in the tumor patients. The ZMC disclosed by the invention has a good clinical application prospect.